Original article
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia

https://doi.org/10.1016/0300-2977(96)00015-0Get rights and content

Abstract

Background: Familial combined hyperlipidaemia (FCH), characterized by elevated very-low-density lipoprotein (VLDL) and/or low-density lipoprotein (LDL), is associated with an increased prevalence of premature cardiovascular disease. Therefore, lipid-lowering is frequently indicated. Methods: We evaluated in a parallel, double-blind randomized fashion the effect of gemfibrozil (1200 mg/day) (n = 40) or simvastatin (20 mg/day) (n = 41) on lipids, apolipoprotein-B (apo-B)-containing lipoproteins, apo-CIII and lipoprotein(a) [Lp(a)], in 81 well-defined FCH patients. Results: While both drugs lowered plasma cholesterol and triglyceride levels, gemfibrozil lowered plasma triglycerides more effectively by reduction of triglycerides in VLDL and LDL, whereas simvastatin was more effective in its reduction of total plasma cholesterol by exclusively decreasing LDL cholesterol. High-density lipoprotein (HDL) increased to an equal extent on both therapies. Total serum apo-B levels were reduced with both drugs; however, gemfibrozil decreased apo-B only in VLDL + IDL, whereas simvastatin decreased apo-B in both VLDL + IDL and LDL. In keeping with a more effective reduction of VLDL particles, a more pronounced reduction of apo-CIII also was observed after gemfibrozil, which correlated with the reduction in plasma triglycerides. Baseline concentrations of Lp(a) showed a wide range in both treatment groups. Median Lp(a) levels increased after simvastatin, but were not affected by gemfibrozil. Conclusion: Both therapies exhibited their specific effects, although none of the drugs alone completely normalized the lipid profiles of these patients with FCH. Therefore, the choice of treatment should be based on the most elevated lipoprotein fraction, and in some cases a combination of the two drugs may be indicated.

References (42)

  • SM Grundy et al.

    Familial combined hyperlipidemia workshop

    Arteriosclerosis

    (1987)
  • JE Hokanson et al.

    Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

    Arterioscler Thromb

    (1993)
  • SJH Bredie et al.

    Inherited susceptibility determines the distribution of dense low density lipoprotein subfraction profiles in familial combined hyperlipidemia

    Am J Hum Genet

    (1996)
  • POJ Kwiterovich

    Genetics and molecular biology of familial combined hyperlipidemia

    Curr Opin Lipidol

    (1993)
  • AFH Stalenhoef et al.

    Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia

    Arteriosclerosis

    (1986)
  • SP Babirak et al.

    Familial combined hyperlipidemia and abnormal lipoprotein lipase

    Arterioscler Thromb

    (1992)
  • AP Wojciechowski et al.

    Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24

    Nature

    (1991)
  • HN Ginsberg et al.

    Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI

  • J Loscalzo

    Lipoprotein(a)

  • M Castro Cabezas et al.

    Lipoprotein(a) plasma concentrations associated with lipolytic activities in eight kindreds with familial combined hyperlipidemia and normolipidemic subjects

    Metabolism

    (1993)
  • SM Grundy

    HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

    N Engl J Med

    (1988)
  • Cited by (0)

    Part of this work was presented at the “Internistendagen” Veldhoven, The Netherlands, 1995 (Neth J Med 1995;46:A68).

    View full text